98.75% year-over-year gain with Momentum Score A; positioned as leading healthcare services player serving government-sponsored programs; recent 6.4% weekly decline presents momentum buying opportunity
Strong operational cash flow of ~$8 billion, significant debt reduction (debt-to-capital ratio improved from 46.5% to 41.6%), successful monetization of receivables, and stock gaining 58.2% year-to-date. Company maintains Zacks Rank #1 (Strong Buy) with forward P/E of 12.48 below industry average.
Strong Q2 results with EPS of $2.51 vs. loss of $0.16 YoY, improved health benefits ratio (89.6% vs. 93%), reaffirmed 2026 EPS guidance above $4.80, and profitability recovery in Marketplace and Medicare segments. Stock has surged 60.4% YTD and carries a Zacks Rank #1 (Strong Buy) with a Value Score of A.
Strong earnings beat track record (4 consecutive quarters), significant year-to-date outperformance (+68.7%), attractive valuation metrics (14.2X forward EPS below peer average of 23.1X, PEG ratio of 0.44), Zacks Rank #1 Strong Buy rating, and 'A' Value and Growth scores indicate strong fundamentals and upside potential.
Centene shows improving fundamentals with health benefits ratio improvement from 90.9% to 89.5%, MA approaching breakeven, strong YTD stock performance (+59%), attractive valuation (P/E 12.57 vs industry 15.80), and Zacks Rank #1 Strong Buy rating with consensus 2026 earnings growth of 135.1%.
Centene faces significant headwinds including a 2 million member loss in ACA plans, total membership decline of 1.63 million year-over-year, and the need for workforce reductions through voluntary buyouts. The company's stock declined 2.08% on the news, reflecting investor concern about declining revenues and profitability challenges.
Stock declined 20.85% despite reaffirming 2026 earnings guidance; Mizuho lowered price target to $41 and maintains Neutral rating, suggesting limited upside
Articles that tag CNC but are mainly about other companies.
Zacks Rank #1 (Strong Buy) rating, 7% consensus earnings estimate increase over 60 days, PEG ratio of 0.39 (favorable vs. industry 1.39), and Growth Score of A indicate strong fundamentals and valuation.
Stock gained 98.75% over the past year with a Momentum Score of A, indicating strong long-term performance despite a 6.4% weekly decline. The pullback is viewed as a buying opportunity within a strong uptrend.
Zacks Rank #1 (Strong Buy) rating with 32.4% long-term earnings growth expectation and exceptional 151.3% average trailing four-quarter earnings surprise demonstrate outstanding financial results.
Largest individual holding in RPV at 2.68% of portfolio. Mentioned factually without performance commentary or valuation assessment.
Expected earnings growth exceeding 100% with consensus estimates improved 40.9% over 60 days; Zacks Rank #1 rating; diversified healthcare company with stable government-sponsored program revenue model
Raised 2026 adjusted EPS guidance to above $4.80 from above $3.40 (130.8% increase), increased revenue guidance, maintains attractive forward P/E of 13.58X below industry average, and holds Zacks Rank #1 with 68.7% year-to-date gains.
CNC carries a Zacks Rank #1 (Strong Buy) with nine upward revisions in 60 days, perfect earnings beat record (4 of 4 quarters) with remarkable 151.3% average surprise, and large revenue base of $196.3 billion.
Expected to deliver over 100% earnings growth this year with 40.9% improvement in consensus estimates over 60 days. Holds Zacks Rank #1 (Strong Buy) rating.
Zacks Rank #1 Strong Buy rating with significant 40.9% consensus earnings estimate increase over 60 days, favorable PEG ratio of 0.40 vs industry 1.43, and Growth Score of A indicate strong growth potential.
Zacks Rank #1, beat earnings consensus in all 4 consecutive quarters with 151.3% average beat, current-year EPS estimate surged 135.1% year-over-year
Exceptional earnings growth exceeding 100% for current year, disciplined pricing and portfolio optimization, favorable Medicaid rate actions, and forward P/E of 13.70X well below industry average of 23.44X
Listed as the largest individual holding in RPV (2.68% of assets) with no qualitative assessment provided; mentioned factually as part of portfolio composition.
Fundamental recovery gaining strength with improved profitability, raised full-year 2026 EPS guidance to >$4.80, 4% revenue growth, improved HBR metrics, strong operating cash flow of $3.6 billion, and 151.28% average earnings surprise.
Zacks Rank #1 (Strong Buy) with positive earnings estimate revisions, perfect earnings beat record (4 of 4 quarters) with exceptional 151.3% average surprise, indicating strong operational execution.
Zacks Rank #1 rating, 40.9% increase in consensus earnings estimate over 60 days, favorable PEG ratio of 0.35 vs. industry 1.28, and Growth Score of B indicate strong buy potential.
Expected earnings growth exceeding 100% for current year, Zacks Consensus Estimate improved 40.9% over 60 days, Zacks Rank #1 (Strong Buy)
Stock gained 25.68% after reporting better-than-expected Q1 results with multiple analyst price forecast increases
Stock edged up only 0.48%, suggesting minimal market reaction despite the positive Medicare Advantage payment news
Stock declined 10.5%, making it the worst performer among Russell 1000 stocks on the day.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
